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Introduction: Immunodeficiency can occur both in patients undergoing radiation therapy, as well as in patients
who have had thymectomies. However, few studies have examined the immune recovery of a patient following
both procedures. We aim to emphasize the need for assessment and consistent monitoring of patients with
thymoma prior to and after combined treatment of thymectomy and radiation, both of which are likely to result
in an increased risk for immunodeficiency.
Case presentation: We describe the longitudinal progress of a 59-year-old Asian male who underwent thymectomy
followed by radiation therapy and subsequently presented with generalized urticaria. Revelation of a low absolute
lymphocyte count (615 cells/mcL) on initial evaluation prompted further analysis of his immunoglobulin levels and
antigen response to a polysaccharide pneumococcal vaccine (PneumoVax-23). Although his immunoglobulin levels
were unremarkable, he failed to respond to 11 of 12 serotypes of the pneumococcal vaccine. As a result, he was
placed on Bactrim® (trimethoprim-sulfamethoxazole) prophylaxis to prevent opportunistic infections, and his CD4+
and CD8+ counts were monitored over the course of 8 years. His lymphocyte counts 87 months after thymectomy
and 85 months after radiation therapy were as follows: absolute lymphocyte count 956 cells/mcL, absolute
CD3+/CD4+ 164/mm3 (16%) and absolute CD3+/CD8+ 257/mm3 (25%). The patient was able to discontinue
Bactrim® (trimethoprim-sulfamethoxazole) prophylaxis after 9 years of treatment.
Conclusions: The lymphocytopenia, low CD4+ count, and failed response to pneumococcal vaccination that
presented in our patient are consistent with immunodeficiency. After radiation alone, a recovery of T-lymphocytes is
usually observed after approximately 3 weeks. Over the course of 8 years, he has still not made a full recovery according
to laboratory markers, which seem to have stabilized at chronically low levels. To prevent serious complications, we
suggest that patients who have undergone both thymectomy and radiation therapy be monitored for immunodeficiency.
This case report informs the practices of allergists, oncologists, and neurologists in the continuing care of patients with
thymoma.
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The thymus, an organ composed of lymphoid and
epithelial tissue, is located in the anterior superior
mediastinum and responsible for the selection and
maturation of T-lymphocytes. On the onset of puberty,
the thymus begins to involute, shrinking in size
throughout adulthood and leading to a profound decline
of thymic function by early adulthood. Thymoma, arising
from the epithelial cells, is an uncommon tumor of the* Correspondence: asthma4@yahoo.com
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article, unless otherwise stated.thymus and is typically treated with surgical excision.
Induction and/or adjuvant chemotherapy may be used
if the invasion of the tumor infiltrates into surrounding
tissue. A commonly used regimen in current practice is
cisplatin-based chemotherapy. However, there are no
randomized trials that evaluate the effectiveness of
chemotherapy for thymic carcinoma or advanced thymoma
in adults [1]. Furthermore, the prognosis of patients with
totally resected stage III and stage IV thymoma was not
improved with adjuvant therapy [2].
Radiation therapy of the mediastinum causes a rapid
decrease in circulating B- and T- lymphocytes. While the
acute decrease in lymphocytes post-procedure is shortoMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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both numbers and function of circulating lymphocytes
[3,4]. CD4+ lymphocyte recovery after dose-intense
chemotherapy is constrained in adults both by a limited
thymic regenerative capacity, as well as an increased
susceptibility to apoptosis within the expanding peripheral
CD4+ population [5,6]. In a study of children and young
adults exposed to chemotherapy, the thymopoietic
pathway of CD4+ T-lymphocyte regeneration was shown
to be important throughout childhood. However, it is
unclear whether there is an age after which the thymus
loses it regenerative capacity completely [7].
Thymectomy is a common therapeutic option to treat
myasthenia gravis (MG), a condition commonly associated
with thymoma. In a long-term study of patients who had
undergone a thymectomy, laboratory work demonstrated
a mild T-cell lymphocytopenia and an expansion of some
V-beta families among the circulating CD4+ and CD8+ T
cells, as well as organ and non-organ-specific autoantibodies
[8]. A more recent study suggested that extrathymic
development of T-cells in the tonsils supports the gener-
ation of autoreactive T-lymphocytes, and may even
contribute to malignant transformation [9]. Extrathymic
T-cell development suggests an increase of systemic
autoimmune disease secondary to thymectomy in patients
with MG [8], possibly explaining the development of
systemic lupus erythematosus (SLE) in patients months or
years after surgical thymectomy [10]. This discovery
assumes an important role in adults who have undergone
chemotherapy, accounting for increased autoimmunity in
these patients [11,12].
In this case report, we present a patient who developed a
significant, sustained CD4+ lymphocytopenia and chronic
idiopathic urticaria after a combination of thymectomy and
radiation as treatment for thymoma.
Case presentation
Over 9 years ago, a 59-year-old Asian man was referred
to our office by his primary care physician with a history
of extensive daily hives consisting of severe itching for the
past 3 to 4 months. While his skin rash was aggravated by
stress and cold weather, there was no association with any
foods or medications. The only unusual aspect of his past
medical history was a microinvasive thymoma involving
the capsule, which was diagnosed 2 years prior to his
appointment at our office. Before treatment of the
thymoma, his white cell and absolute lymphocyte
counts were within normal limits; however, his CD4+ and
CD8+ counts were not measured prior to surgery. Six
weeks following the thymectomy to remove the tumor, he
received mediastinal radiation of 62 gray. His rash began
approximately 2 weeks after his thymectomy. Two months
following the completion of chemotherapy, he sought
care. While his immune function had not been specificallyevaluated prior to his thymectomy and radiation, his
medical history was negative for any known immune
disorders, and he indicated no previous symptoms for
immune disorders. Furthermore, his family history
was negative for autoimmune disorders. The physical
examination on his initial visit was only significant for
extensive urticarial rash on his trunk and both extremities
with no angioedema.
Two months after the radiation was delivered, our initial
laboratory work-up was significant for a depressed absolute
lymphocyte count of 465 cells/mcL (normal values, nml:
850 to 3900 cells/mcL). The combination of his low
absolute lymphocyte count and non-allergic urticaria
prompted further laboratory evaluation of a complete
blood count differential, CD4+ and CD8+ counts, thyroid-
stimulating hormone (TSH), and thyroid autoantibodies.
We diagnosed him as having chronic idiopathic urticaria
(CIU) and prescribed fexofenadine 180mg once daily
before noon and doxepin 50mg every evening at bedtime.
A subsequent follow-up visit a month later revealed a
severe CD4+ lymphocytopenia of 75/mm3 (10.9%; nml
490 to 1740/mm3, 30 to 61%) with CD8+ cell count at
336/mm3 (49%; nml 180 to 1170/mm3, 12 to 42%); however,
his TSH, thyroid peroxidase, and thyroglobulin antibodies
were within normal limits. He tested negative for human
immunodeficiency virus. Although his immunoglobulin
levels were unremarkable, he failed to respond to 11 of 12
serotypes of the polysaccharide pneumococcal vaccine. To
prevent opportunistic infections, we prescribed him Bactrim®
(trimethoprim-sulfamethoxazole) double strength once daily
prophylaxis. Over the next few weeks, his urticaria improved
between 40 and 50%, albeit he continued to experience a
daily rash and frequent itching.
For 2 years after his first appointment at our office, he
was followed every 4 weeks with close monitoring for
any opportunistic infections and every 2 to 3 months
with laboratory evaluation for CD4+ and CD8+ counts.
Fifteen months following his thymectomy, he developed
a severe case of shingles on his trunk and left arm,
for which he was treated with Famvir® (famciclovir)
500mg twice daily and Zovirax® (acyclovir) cream twice
daily. He continued to have severe, persistent CD4+
lymphocytopenia, reaching a maximum of 130 cells/mm3
(nml: 490 to 1740/mm3, 30 to 61%) over the course of
2 years post-thymectomy (Table 1).
One year later and a total of 3 years after his thymectomy,
his yearly positron emission tomography/computed
tomography (PET/CT) scan revealed a small posteriorly
located right apical lung nodule with mild metabolic
activity. A needle biopsy of the nodule was inconclusive.
However, a PET/CT scan a year later showed that the
mass had increased by 3mm. As a result, he received a
right thoracoscopy and wedge resection of the nodule in
his right lung, a total of 47 months since his thymectomy.
Table 1 Report of our patient’s absolute lymphocyte counts over 7 years post-thymectomy: CD3+/CD4+ T-cell counts










8 685 75 10.9 336 49.0
9 755 85 11.3 366 49.0
13 912 98 10.8 434 47.6
16 737 87 11.8 345 46.8
19 851 102 12.0 369 43.4
24 1318 130 9.9 554 42.0
31 1281 128 10.0 461 36.0
36 1321 136 10.4 428 32.6
42 1235 126 10.2 378 30.6
54 1060 160 15.1 306 28.9
60 888 131 14.0 253 26.0
67 774 145 18.0 227 28.0
79 846 160 18.0 241 27.0
85 956 164 16.0 257 25.0
Age-appropriate levels 850–3900 490–1740 30–61 180–1170 12–42
All of our patient’s laboratory values are arranged by month post-thymectomy. Laboratory values include absolute lymphocyte count, CD3+/CD4+ absolute count,
CD3+/CD4+ percentage, CD3+/CD8+ absolute count, and CD3+/CD8+ percentage. Age-appropriate laboratory values have been provided in the last row.
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was inflammatory in nature with granulomatous features.
In the following 3 years since the lung resection, we
monitored him with a physical examination every 2 to
3 months and a laboratory work-up every 4 to 7
months. He continued to complain of hives consistent
with CIU. During this time, he maintained his drug
plan of doxepin 50mg every evening at bedtime, fexo-
fenadine 180mg once daily before noon, and Bactrim®
(trimethoprim-sulfamethoxazole) double strength once
daily prophylaxis. As in the months before, he experienced
CD4+ lymphocytopenia, wavering between approximately
130/mm3 and 160/mm3. During the 3 years preceding his
last visit, he experienced no recurrent sinopulmonary
or opportunistic infections for 3 years while maintaining
Bactrim® (trimethoprim-sulfamethoxazole) prophylaxis.
This allowed for discontinuation of the prophylaxis
treatment, contingent on close monitoring of his health and
resumption of Bactrim® (trimethoprim-sulfamethoxazole) if
symptoms occurred. His last laboratory work-up at our
office, approximately 85 months after his thymectomy,
revealed an absolute lymphocyte count of 956 cells/mcL,
absolute CD3+/CD4+ of 164/mm3 (16%), and absolute
CD3+/CD8+ of 257/mm3 (25%): nml 850 to 3900 cells/
mcL; 490 to 1740/mm3, 30 to 61%; 180 to 1170/mm3, 12 to
42%, respectively (See Figures 1 and 2).
Discussion
The laboratory results from our patient suggest a sta-
bilization of CD4+ cell counts, which is consistent withother patients who experienced similar therapies. According
to research involving patients with head and neck tumors,
similar cellular immune system disturbances in individual
patients were noted 11 years post-radiation therapy. Our
study, as well as others, shows that radiation-induced T-cell
deficiency in patients may be irreversible [13]. While
radiation therapy to the thymus is detrimental to the
T-cell pool, thymus resection does not necessitate immu-
nodeficiency. It has been shown that only thymectomies
where the thymus was active at the time of surgery result in
a marked decrease in peripheral T-cell concentration. In
patients for whom thymopoiesis was minimal, there was
little effect on T-cell concentration [14].
In addition to chronic T-cell lymphocytopenia, our
patient also developed chronic idiopathic urticaria, a
condition that we hypothesize is autoimmune. There is
mounting evidence of autoimmune diseases developing
in patients undergoing thymectomy with or without
pre-existing MG, suggesting a role of thymectomy in the
induction of autoantibodies [15-17]. However, thymectomy
may exert contrasting effects on the course of distinct
autoimmune diseases. In certain instances, a thymectomy
may relieve the source and therefore the symptoms of a
pathological condition. In other situations, thymectomy
may precipitate a clinical deterioration or even create a
new disease, suggesting a protective role of the thymus
against autoimmunity. For example, thymoma-induced
immunodeficiency, commonly known as Good syndrome,
is characterized by hypogammaglobulinemia, low or absent
B-cells in peripheral blood, and variable defects in
Figure 1 Absolute lymphocyte count over 7-year period. The patient’s absolute lymphocyte counts measured in cells/mcL are shown based
on the amount of time in months post-thymectomy. The blue data points represent the patient’s lymphocyte counts. Age-appropriate lymphocyte
counts are represented by the red vertical bracket, with normal values provided to the right of the bracket.
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syndrome is to first remove the thymic tumor and to then
follow up with immunoglobulin replacement [20].
However, unlike our patient, patients with Good syndrome
do not manifest with severe CD4+ lymphocytopenia. Our
patient’s lymphocytopenia, as well as his development ofFigure 2 CD3+/CD4+ and CD3+/CD8+ absolute counts over 7-year peri
measured in cells/mm3 are shown based on the amount of time in months p
counts; the blue data points represent CD3+/CD4+ absolute cell counts. Age-
values provided in the adjacent boxes. The red bracket corresponds to norma
normal CD3+/CD4+ absolute cell counts.autoimmune symptoms following thymus resection,
suggest that our patient’s thymectomy in conjunction with
his radiation therapy, are likely culprits for immunodefi-
ciency, and not his thymoma.
Another possible explanation for our patient’s condition
is that he had a pre-existing autoimmune disorder andod. The patient’s absolute T-cell counts of CD3+/CD4+ and CD3+/CD8+
ost-thymectomy. The red data points represent CD3+/CD8+ absolute cell
appropriate T-cell counts are represented by the vertical brackets, with
l CD3+/CD8+ absolute cell counts, and the blue bracket corresponds to
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disease diagnosed in patients who later develop thymoma is
MG, while less likely conditions in this setting are SLE,
pure red blood cell aplasia, hypogammaglobulinemia,
rheumatoid arthritis, and dermatomyositis [21]. While we
cannot be certain our patient did not have some subclinical
manifestation of any number of these conditions, it is
highly unlikely given his medical records and history.
Our patient did not have any immune work-up after
being diagnosed with thymoma, or immediately after his
thymectomy and radiation treatment. We do not know
if he had immune defects as a result of the thymoma, or
if he developed the severe CD4+ lymphocytopenia
entirely secondary to thymectomy and/or radiation.
Although our patient’s history appeared to be negative
for immunodeficiency before his thymectomy, we advise
that patients with thymoma should receive an immune
work-up including CD4+ and CD8+ counts prior to
treatment. Awareness of immunodeficiency in a patient
may help physicians quickly identify opportunistic
infections, the need for prophylaxis, and his or her
tolerance for vaccines. For example, our patient was
placed on Bactrim® (trimethoprim-sulfamethoxazole)
double strength once daily prophylaxis as a precaution to
decrease the likelihood of infection in his immunodefi-
cient state.
Conclusions
Our patient presented with a persistent low CD4+ T-cell
count for 8 years following a combination of thymectomy
and radiation therapy for thymoma. This case dictates the
need for an awareness of autoimmune disorders in
patients with similar treatment histories. We recommend
that patients with thymoma with or without thymectomy/
radiation therapy should be considered for an immune
work-up both prior and subsequent to treatment.
Continuous monitoring of their immune dysfunction
may be critical, especially within the first year of
treatment. Prospective studies must be conducted to
assess immunodeficiency and autoimmune disorders in
patients that have had both thymectomy and radiation.
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